Masuyo Miyake

Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer

Kei Kawaguchi, Kentaro Miyake, Qinghong Han et al. · Cancer Letters · 2018 · 86 citations

Medicine, Oncology, Pharmacology +6

Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic

Kentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna et al. · Cell Cycle · 2018 · 74 citations · Full text

Medicine, Oncology, Pharmacology +17

Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma

Kentaro Igarashi, Kei Kawaguchi, Shukuan Li et al. · Cancer Letters · 2018 · 66 citations

Medicine, Oncology, Pharmacology +12

Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention

Kei Kawaguchi, Qinghong Han, Shukuan Li et al. · Cell Cycle · 2017 · 59 citations · Full text

Medicine, Oncology, Pharmacology +16

Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer

Kei Kawaguchi, Kentaro Miyake, Qinghong Han et al. · Cell Cycle · 2018 · 47 citations · Full text

Medicine, Oncology, Pharmacology +17